Press Releases Press Releases Keyword Search Year None2022202120202019201820172016201520142013 20 Jun '2022 XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study 28 Apr '2022 XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer 02 Feb '2022 XBiotech Inks Clinical Manufacturing Deal 26 Jan '2022 XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
Press Releases Keyword Search Year None2022202120202019201820172016201520142013 20 Jun '2022 XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study 28 Apr '2022 XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer 02 Feb '2022 XBiotech Inks Clinical Manufacturing Deal 26 Jan '2022 XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
28 Apr '2022 XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
26 Jan '2022 XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
